Tamoxifen calms down the distressed PDAC stroma

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest human cancers and is associated with extensive desmoplastic changes in the tumor microenvironment. In this issue of EMBO Reports, two studies by Cortes et al identify the G-protein-coupled estrogen receptor (GPER) as an important regula...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Pein, Maren (VerfasserIn) , Oskarsson, Thordur (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2019
In: EMBO reports
Year: 2018, Jahrgang: 20, Heft: 1
ISSN:1469-3178
DOI:10.15252/embr.201847334
Online-Zugang:Verlag, Volltext: https://doi.org/10.15252/embr.201847334
Verlag: https://www.embopress.org/doi/full/10.15252/embr.201847334
Volltext
Verfasserangaben:Maren Pein & Thordur Oskarsson
Beschreibung
Zusammenfassung:Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest human cancers and is associated with extensive desmoplastic changes in the tumor microenvironment. In this issue of EMBO Reports, two studies by Cortes et al identify the G-protein-coupled estrogen receptor (GPER) as an important regulator of the PDAC-associated stroma, modulating tissue stiffness, hypoxic responses, and desmoplasia. Intriguingly, the authors find that tamoxifen, which is widely used for its antagonizing effect on nuclear estrogen receptor (ER)-positive breast cancers, acts as GPER agonist to normalize the PDAC microenvironment. The two studies thus open up new opportunities to explore tamoxifen as potential anti-stromal therapy in PDAC.
Beschreibung:Published online 11 December 2018
Gesehen am 21.10.2019
Beschreibung:Online Resource
ISSN:1469-3178
DOI:10.15252/embr.201847334